LATEST PRESS RELEASE

Amorfix announces strategic plan to centralize operations in South San Francisco and focus on neurodegenerative disease

January 12, 2015

View

Amorfix announces second quarter results for period ending September 30, 2014

November 12, 2014

View

Amorfix closes private placement and receives back rights for ALS antibody therapeutic development and commercialization

October 21, 2014

View

Amorfix appoints Dr. Elliot Goldstein and Mr. Warren Whitehead to Board of Directors

September 4, 2014

View

View All Amorfix Press Releases

TSX:AMF listed

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.

Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.

amorfix life sciences